ProCE Banner Activity

CE / CME

Current Essential Testing in Early Breast Cancer

Video

Watch this on-demand webcast featuring expert discussion and presentations on BRCA testing in early breast cancer and the role of adjuvant olaparib.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Nurses: 1.00 Nursing contact hour

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: March 31, 2023

Expiration: March 30, 2024

Share

Faculty

Allison Butts

Allison Butts, PharmD, BCOP

Pharmacist Manager, Oncology
Clinical Pharmacist, Breast Oncology
Program Director, PGY2 Hematology/Oncology Pharmacy Residency
Assistant Adjunct Professor, UK College of Pharmacy
UK HealthCare
Lexington, Kentucky

Charles E. Geyer, Jr.

Charles E. Geyer, Jr., MD

Professor of Medicine
Division of Hematology/Medical Oncology
Department of Internal Medicine
University of Pittsburgh UPMC Hillman Cancer Center
Staff Attending
Breast Medical Oncology
UPMC Magee Womens Hospital
Pittsburgh, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Merck Sharp & Dohme, LLC

Partners

ProCE

ProCE Banner

Target Audience

This program is intended for medical oncologists, pharmacists, NP/PAs, nurses, genetic counselors, pathologists, and other healthcare professionals who care for patients with breast cancer.

Program Learning Goal

The goal of this activity is to improve the knowledge, confidence, and competence of learners to select and integrate new biomarker testing and therapies into individualized treatment plans for early-stage breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Develop genetic testing strategies that incorporate best communication techniques and expert guidance for all patient subgroups with EBC who may benefit from PARP inhibition

  • Communicate to colleagues and patients the improvement in overall survival gained by adding PARP inhibition to the adjuvant treatment of patients with germline BRCA mutations

  • Integrate PARP inhibition into treatment plans and sequence strategies for patients that also may be appropriate for other newly approved treatments for EBC

  • Manage treatment-related adverse events in the early-stage breast cancer setting associated with new treatment options to improve adherence and patient experience and optimize outcomes

  • Identify patients who should be tested for BRCA mutations and communicate to colleagues and patients the rationale and steps for corrective action for those not tested

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty  reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:

Allison Butts, PharmD: consultant/advisor/speaker: AstraZeneca, BeyondSpring. 

Charles E. Geyer, Jr., MD: researcher: AbbVie, AstraZeneca, Daiichi Sankyo, Roche/Genentech; consultant/advisor/speaker: Exact Sciences, Seagen.

The planners and content peer reviewers from Clinical Care Options, LLC and ProCE, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from March 31, 2023, through March 30, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by clicking the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO) and ProCE, LLC. Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hours.

Continuing Pharmacy Education
CCO designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-23-088-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.